Trial Profile

Clinical Trial Assessing the Effecacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Toripalimab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

25 Feb 2024 Status changed from recruiting to completed.
21 Sep 2021 Trial design presented at the 46th European Society for Medical Oncology Congress
13 May 2021 The study protocol amended to change study allocation from randomised to non-randomised. Also, the patients who have received previous first-line platinum-based chemotherapy or immunotherapy (except toripalimab) will be included in this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com